Response Biomedical announces new director

Response Biomedical Corporation recently announced that Jonathan Wang has been appointed to its board of directors.

Wang is the senior managing director for Asia at OrbiMed, one of the world's largest healthcare-dedicated investment firms with nearly $5 billion in assets under management, where he co-founded the company's Asia focused VC fund.

Response Biomedical's new chief executive officer Jeffrey Purvin welcomed Wang back to the board. Wang served as a director from July 2010 to October 2011.

"We are very pleased to have Dr. Jonathan Wang return to the Board of Directors," Purvin said. "During his previous term on the board, as well as in the interim period, Jonathan provided important insights into the China market for Response's point of care products. His long experience in China will be enormously valuable in expanding our presence there."

Wang obtained his PhD in molecular neurobiology from Columbia University, where he trained under the supervision of Nobel Laureate Dr. Eric Kandel. He received an MBA from Stanford University.

Response Biomedical is a developer of on-site diagnostic kits for use with the RAMP detection system. RAMP is capable of detecting anthrax, smallpox, ricin and botulinum toxin in its surrounding environment. The system is entirely portable and uses disposable test cartridges.